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Abstract Perioperative blood loss is a major problem in
elective orthopedic surgery. Allogeneic transfusion is the
standard treatment for perioperative blood loss resulting in low
postoperative hemoglobin, but it has a number of well-
recognized risks, complications, and costs. Alternatives to
allogeneic blood transfusion include preoperative autologous
donation and intraoperative salvage with postoperative auto-
transfusion. Orthopedic surgeons are often unaware of the
different pre- and intraoperative possibilities of reducing blood
loss and leave the management of coagulation and use of
blood products completely to the anesthesiologists. The goal
of this review is to compare alternatives to allogeneic blood
transfusion from an orthopedic and anesthesia point of view
focusing on estimated costs and acceptance by both parties.
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Introduction
Perioperative blood loss is still a major problem in elective
orthopedic surgery. Allogeneic blood transfusion is the
standard approach to treat potentially detrimental decreases
in hemoglobin (Hb) concentration. Inherent risks in homol-
ogous transfusions persist despite all efforts to avoid them.
In addition to well-known risks, such as the transmission of
infections (Table 1), transfusion febrile reactions [22], or
transfusion-related acute lung injury [52], there is some
concern about a causal relationship between allogeneic red
blood cell (RBC) transfusions and immunomodulation.
Immunomodulation is an allogeneic blood transfusion
related immunosuppression, which is thought to increase
the incidence of postoperative infections (up to six times),
delay healing of postoperative wounds, and thereby prolong
hospitalization [7, 8, 24, 45, 74, 90–92].
Another disadvantage of allogeneic blood transfusions is
the cost. Reported cost per unit of packed red cells has
varied between $270 and $780, depending on further costs
for storage, laboratory analyses (cross match tests, antibody
tests, etc.), and other postdonation processing. Actual
ﬁgures in Switzerland show that the cost for one RBC unit
in surgery is $500, without taking into consideration
transfusion-related complications [78].
In view of the possibility that public health systems may
face an exponential cost increase for transfusion medicine in
the near future [37, 94], it is the goal of this review article to
compare several alternatives to allogeneic blood transfusion.
Althoughmany review articles have dealt with this issue, most
of them either do not account for most of the alternatives, do
not include cost estimations, or consist only of expert
opinions. Special attention is paid therefore to the cost of the
alternatives, as well as the surgery-speciﬁc drawbacks of each
and the acceptability to orthopedic surgeons.
While the experience and skills of the surgeon are
probably the most important factors inﬂuencing intraoper-
ative blood loss [46, 66], it is also the one factor that cannot
be managed by any other team member. Adequate hemo-
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stasis therefore remains the “gold standard” technique for
eliminating potential complications related to blood loss. Its
impact on transfusion rates is obvious: Blood that is not lost
does not have to be replaced.
Alternatives to allogeneic blood transfusions
Several methods and approaches have been described to
reduce allogeneic blood transfusions in orthopedic surgery.
These include modiﬁcations of the indications for trans-
fusion (transfusion triggers) based on Hb concentration,
predonation of autologous blood, iron substitution, eryth-
ropoietin (EPO) injections, adjustment of perioperative
medication (anticoagulation, nonsteroidal anti-inﬂammatory
drugs (NSAID)), body temperature adjustments, goal-
directed transfusions, hypotensive epidural anesthesia,
normovolemic hemodilution, application of platelet gel/
ﬁbrin gel to the surgical site, and intraoperative capture and
transfusion of lost autologous blood (Cell Saver/C.A.T.S.
and ABT/Bellovac). Each alternative to allogeneic blood
transfusion has its pros and cons, and in this review, we
describe these in detail.
Adjusting the indications for transfusion
One method to reduce the use of allogeneic transfusion is to
adjust or modify the indications that are based on measured
hemoglobin and hematocrit levels. Despite extensive phys-
iological data, indications for RBC transfusion are not
uniform. Until the 1980s, many transfusion protocols used
the 10/30 rule, which held that hemoglobin must exceed
10 g/dl and hematocrit should be higher than 30% before
operation. This recommendation was later applied to all
transfusion settings, acute or chronic, and led to the choice
of Hb 10 g/dl as the threshold at which transfusion was felt
to be indicated [51]. According to current guidelines from
the American Society of Anesthesiologists, RBC trans-
fusion is recommended if the hemoglobin concentration
drops below 6–10 g/dl. Transfusions over 10 g/dl are rarely
indicated, and transfusions are generally indicated if
hemoglobin falls below 6 g/dl. In Europe, a target range
of 7–9 g/dl is largely accepted, even in major trauma [60].
Hemoglobin levels below 6.4 g/dl have been associated
with impaired cognitive function. Hemoglobin levels below
4.8 g/dl are associated with a mortality of 50% and are
therefore not recommended [97]. Hemoglobin levels alone,
however, do not always justify transfusion. Multiple clinical
factors and hemodynamic parameters should be evaluated
in every case [58], and allogeneic transfusion decisions
should be individualized [85].
Physiological transfusion triggers include tachycardia,
hypotension, oxygen extraction greater than 50%, mixed
venous oxygen pressure of less than 32 mmHg, increase of
lactate, and electrocardiography changes. The severity of
shock, hemodynamic response to resuscitation, and the rate
of actual blood loss in the acutely bleeding and hemody-
namically unstable patient may also be taken into consid-
eration. However, RBC transfusions should be used
sparingly during elective orthopedic surgery.
Given the transfusion triggers that are currently accepted
in clinical practice, it appears that clinical outcomes could
improve signiﬁcantly with more widespread adoption of
restrictive transfusion strategies [25]. The exception to this
approach should include elderly patients with signiﬁcant
comorbidities that increase the risk of complications from a
low hemoglobin. If restriction of transfusion alone is used,
the costs for packed red cells can be decreased, but the
result may include symptomatic patient weakness, pro-
longed hospital stay, and delayed rehabilitation [14]. In
addition, treating surgeons may be hesitant to observe
patients with low Hb levels, hoping to avoid complications
associated with postoperative anemia. Additionally, the
surgeon becomes vulnerable from a liability standpoint if
transfusion below a threshold of 10 g/dl is deemed to be
“standard of care” and he decides to observe rather than
Table 1 Incidences of potential risks associated with allogeneic blood transfusions (adapted from Pape et al.)
Risks associated Incidence References
Volume overload Hypertension, pulmonary edema 1:100–1:1,000 [30]
Mistransfusion Acute hemolytic reaction 1:6,000–1:33,000 [39]
Delayed hemolytic reaction 1:2,000–1:11,000 [39]
Bacterial contamination Sepsis 1:10,000–1:100,000 [30]
Viral contamination HIV 1:2,300,000 [23]
Hepatitis C 1:1,800,000 [23]
Hepatitis B 1:350,000 [23]
Hepatitis A 1:1,000,000 [71]
Cytomegalovirus 1:10–1:30 [71]
Epstein–Barr virus 1:200 [71]
West–Nile virus 1:3,000–1:5,000 [39]
Prion contamination Creutzfeldt–Jakob disease Unknown [23]
Transfusion-related acute lung injury Immune 1:625 [30]
Nonimmune 1:2,800 [30]
Allergic transfusion reaction 1:100–1:2,000 [30, 71]
Immunosuppression 1:1 [71]
Alloimmunization 1:16,000 [71]
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transfuse. Therefore, a better approach would include
optimal patient preparation prior to elective surgery to
reduce the need for allogeneic transfusion, while avoiding
the problems associated with symptomatically reduced red
cell mass [14].
Autologous blood donation
Autologous blood donation has been proposed as a method
to help avoid the need for allogeneic transfusion in the
perioperative period. This method is used 4–6 weeks in
advance of elective surgery in patients who have an
expected intraoperative blood loss of more than 1.5 l.
Patients donate one or more units of autologous blood
preoperatively. A recovery period of about 4 weeks is
required prior to surgery. The units are stored in a blood
bank until they are needed. The units can either be
transfused preoperatively (not later than 72 h before
surgery) [93] or kept refrigerated in case of postoperative
need. Blood bank handling is similar to that of allogeneic
blood. Contraindications to predonation include cardiac
risks such as unstable angina, myocardial infarction within
the previous 3 months, coronary artery stenosis involving
the left coronary artery, congestive heart failure, and
signiﬁcant aortic valve stenosis with an Aa gradient >
70 mmHg [49].
The existing literature regarding predonation is conﬂict-
ing. Although several orthopedic trials have reported a
possible reduction of the patient’s relative risk of receiving
an allogeneic blood transfusion when predonation was used
[44, 101, 102], several studies have been published which
question the routine use of predonation in elective orthope-
dic surgery [86, 89]. Described risks include transfusion
reactions, circulatory volume overload, bacterial contami-
nation, and clerical errors [35]. It is a time-consuming
method which can present logistical problems and may lead
to wastage up to 45% of donated blood [31, 35].
Predonation has been declining in popularity for elective
orthopedic surgery since 2002 [54]. A cost–effectiveness
analysis in total hip arthroplasty found no signiﬁcant
difference in complication rate between predonation of
autologous blood and allogeneic transfusion [42]. Further-
more, the method is not cost-effective if:
1. At least one unit of allogeneic blood must be transfused
despite previous autologous donation
2. More than 15% of the donated blood must be discarded
[40]
Preoperative strategies to avoid transfusion
A preoperative strategy that can be used to help avoid the
need for postoperative transfusion is intravenous adminis-
tration of iron. Since iron deﬁciency anemia is the most
common anemia among patients undergoing orthopedic
surgery (prevalence of up to 21%) [89], preoperative iron
supplementation has been proposed in order to elevate
hemoglobin levels [98]. Iron can be supplemented both
orally and parenterally, but intravenous administration is
ﬁve times more effective in inducing the erythropoietic
response after signiﬁcant blood loss [98]. A recent study
reported diminished transfusion requirements after abdomi-
nal hysterectomy with preoperative intravenous iron admin-
istration [21]. In combination with EPO, it has been shown
to decrease not only transfusion rate but also infection rate
and mortality [16–18]. Although iron therapy has been
found to be generally safe and effective, especially high
molecular weight iron, dextran has the disadvantage of
potentially life-threatening dextran-associated anaphylactic
reactions [12]. Recently, a novel intravenous iron prepara-
tion of ferric carboxymaltose (FERINJECT®, Vifor Int., St.
Gallen, Switzerland) has been developed and is a part of
current ongoing trials. It offers the advantage of being well
tolerated; however, the possibility of overdose may be an
issue [53]. More clinical trials are needed to determine the
optimal method of preoperative iron therapy [6].
Iron supplementation and EPO administration work
synergistically. Therefore, they are often recommended as
combination therapy [15, 19, 38] to maximize effectiveness
and minimize suspected risks of thrombosis (with EPO
alone) [31] and depletion of endogenous erythropoietin
reserves (with iron alone) [89].
The costs for iron therapy depend upon the amount to be
given and the cost of the drug. Assuming an average patient
requires 1 g of iron, the cost for the treatment with ferric
carboxymaltose would be $300. That is expensive but still
cheaper than one unit of packed RBCs [78]. Iron supple-
mentation is well accepted by patients and surgeons. A
possible disadvantage is the delay between iron adminis-
tration and the resultant increase in Hb concentration, which
makes the method less useful in emergency cases.
Erythropoietin is a glycoprotein hormone, which is
mainly produced by the kidneys and that is considered to
be the most important regulator of erythropoiesis [27, 47].
EPO increases hematocrit values when given without
concurrent phlebotomy for autologous blood donation [3].
Therefore, there is a potential risk of thromboembolic
complications from the elevated hematocrit. Therefore,
phlebotomy for autologous blood donation is recommended
if the hematocrit rises above 50% during EPO therapy to
reduce the risk of thrombotic complications [63]. The
optimal dosage of EPO prior to elective orthopedic surgery
has not been determined. The lowest effective dose
described is 100 IU/kg of rHuEpo given twice a week for
2 weeks [75]. Assuming an average patient weighs 70 kg,
this treatment would cost about $600. In one study, patients
in The Netherlands with preoperative hemoglobin levels
between 10 and 13 g/dl received an increased dosage,
600 IU/kg of EPO once a week starting 3 weeks before the
scheduled surgery [65]. A high dose of 40,000 IU, given
three times preoperatively, has been shown to be extremely
efﬁcient but costs about $3,000 [13]. Relative contra-
indications to EPO administration include personal and
familial history of thromboembolic events, severe hyper-
tension, allergy, pregnancy, or breastfeeding.
It is unclear whether the withdrawal of EPO, at the
conclusion of therapy, may have any detrimental effects. A
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process called neocytolysis has been described, in which the
rapid fall of EPO levels may negatively inﬂuence eryth-
ropoiesis [13]. It has not yet been reported upon EPO
withdrawal but remains a theoretical concern.
Patients requiring surgery are often on a variety of
medications which may impact perioperative blood loss and
contribute to the fall in hemoglobin concentration after
surgery. Anticoagulation with vitamin K-antagonists or
aspirin is important to elicit in the patient’s history. It is
common to discontinue the use of such agents several days
before surgery. However, discontinuation of agents such as
clopidogrel and aspirin in patients with unstable coronary
perfusion and/or recently implanted stents before elective
orthopedic surgery has been reported to result in unaccept-
ably high risks for thromboembolic events [10, 11, 82, 83].
While aspirin is a lifelong therapy, clopidogrel is usually
prescribed until the coronary stents are fully endothelial-
ized. This usually takes 6–24 weeks for bare metal stents,
but clopidogrel must be taken for 1 year after implantation
of drug eluting stents [11]. The hemorrhagic risk with
antiplatelet therapy is modest with an estimated 2.5–20%
more blood loss with patients continuing aspirin and 30–
50% with the combination of aspirin and clopidogrel [11].
Discontinuation or reducing the therapy to aspirin alone
would be recommended only when bleeding might occur in
a closed space (e.g., intracranial neurosurgery), when an
extremely high blood loss (>2 l) is estimated, or when
aspirin is only used at a preventative dose (81 versus the
325 mg therapeutic dose) [83].
The use of NSAIDs should also be elicited in the
patient’s history. It is generally recommended that all
NSAIDs should be stopped at least 24 h before surgery.
NSAIDs are also widely used for perioperative analgesia
and might adversely affect hemostasis. Selective COX 2
inhibitors may not cause impaired platelet aggregation,
prolonged bleeding time, and increased intraoperative blood
loss, making this class of drug better suited for perioper-
ative pain relief [80, 96].
Perioperative strategies to reduce intraoperative blood
loss
Body temperature during surgery can be manipulated to
affect intraoperative bleeding. Body temperature has been
shown to affect both platelet aggregation and bleeding time.
Even slight decreases of body core temperature of only
1.5°C were associated with increased blood loss of about
50% during total hip replacement [76, 99]. Maintenance of
physiologic body temperature thus seems to be important
for controlling blood loss, and special attention to the
patient’s core temperature should be paid by the surgical
team.
Goal-directed transfusion is another strategy that can be
used to help reduce preoperative blood loss and need for
allogeneic blood transfusion. The principle of goal-directed
transfusion is to optimize the coagulation pathway before a
transfusion is given. This is done by replacing essential
coagulation factors. Fibrinogen and the prothrombin com-
plex (concentrate of factors II, VII, IX, and X, antithrombin
III, protein C) are able to improve coagulation and
minimize blood loss [32, 33]. The method can only be
applied if coagulation is continuously monitored during
surgery by a point-of-care (POC) coagulation monitoring
device. Rotation thromboelastometry (ROTEM®, Penta-
pharm, Munich, Germany) and thromboelastography
(TEG®, Hemoscope, Niles, IL, USA) are examples of such
devices. These powerful tools can help to determine the
causes of hemorrhage. The tests are performed with whole
blood which allows conclusions to be made about the whole
clotting process, ﬁbrinolysis, and platelet function, with
results available quickly at the bedside [34, 57]. In
combination with a transfusion algorithm, this has been
shown not only to decrease the transfusion requirements
during surgery but also to be cost-effective [1, 79, 84]. The
Society of Thoracic Surgeons and the Society of Cardio-
vascular Anesthesiologists both conﬁrm these positive
results and recommend the guidance by POC tests for
coagulation products [29].
The technique of hypotensive epidural anesthesia (HEA)
is not widely performed in orthopedics yet. Nevertheless, it
is a readily available and effective method to reduce
perioperative blood loss [70]. The aims of this method are
to achieve an epidural dermatome block at least as proximal
as the T2 level and to establish a dense block of the cardio-
acceleratory ﬁbers of the thoracic sympathetic chain.
Bradycardia is usually prevented by continuous intravenous
infusion of a low-dose epinephrine solution. This leads to
reduced arterial pressure while heart rate, central venous
pressure, stroke volume, and cardiac output are maintained
in the normal range. Mean artery blood pressure can be
lowered to 50 mmHg resulting in a reduction of intra-
operative blood loss of up to 40% [69] and decreased
postoperative wound drainage, as seen in several orthopedic
trials [26, 48, 87]. HEA seems to be an attractive alternative
from a patient’s point of view. It is, however, limited to
procedures amenable to regional anesthesia and requires an
anesthesia team which is comfortable and proﬁcient in
administration of HEA.
Normovolemic hemodilution is a procedure in which 2–
4 units of whole blood are withdrawn from the patient in the
operating theater just prior to the start of surgery and
replaced with acellular ﬂuids (e.g., colloids or crystalloids).
The advantage of this procedure is that fewer erythrocytes
are lost in case of bleeding during the surgical procedure.
Additionally, fresh whole blood is instantly available for
autologous retransfusion. The procedure has been shown to
reduce the need for allogeneic blood transfusion in other
surgical specialties [41, 61, 88, 100] as well as in
orthopedic surgery [5, 36]. These results could, however,
not be conﬁrmed in two meta-analyses [9, 77]. The
contraindications for normovolemic hemodilution are
severe anemia, hemorrhagic shock related to trauma, active
sepsis, respiratory failure, and myocardial insufﬁciency
[67].
Hemodilution is a patient friendly method that is easy to
perform. Monk et al. estimated the cost for normovolemic
hemodilution at $30, compared with $226 per unit of red
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blood cells [64]. Hemodilution, especially when hydrox-
yethyl starch is used as the volume expander, can lead to
aspirin-like intraoperative bleeding from capillaries due to
reduced platelet aggregation caused by colloids. In proce-
dures where well-controlled hemostasis is necessary, nor-
movolemic hemodilution might not be ideal.
Use of thrombotic agents
The intraoperative use of directly applied thrombotic agents
can reduce blood loss and the need for allogeneic blood
transfusions. Platelet gel is manufactured from platelet rich
plasma which is obtained after the sequestration of
autologous whole blood with a blood cell separator. Treat-
ment involves direct application of concentrated platelets
and their growth factors, especially platelet-derived growth
factor and transforming growth factor-β, which augment the
wound healing cascade [68, 72, 103]. Platelet gel is very
cost-effective (about $24 per unit of blood sequestered) and
efﬁcient in orthopedic surgery. Because of the high
concentration of leucocytes and, in particular, granulocytic
neutrophils which contain myeloperoxidase (a substance
known to remove bacteria), it may be speculated that
platelet gel may also have antibacterial properties [56].
Approximately 350 ml of venous blood is collected intra-
operatively, processed in a centrifuge, fractioned into blood
components, and then sprayed onto the surgical ﬁeld [28].
Fibrin sealants (also known as ﬁbrin glues) are plasma-
derived surgical hemostatic agents. They replicate the ﬁnal
steps of the physiologic coagulation cascade to produce a
stable ﬁbrin clot. Generally, two major components are
present: ﬁbrinogen (with or without factor XIII) and
thrombin (plus calcium with or without antiﬁbrinolytic
drugs). Fibrin sealants can be applied to the surface of the
wound using a dual syringe system in a liquid or an aerosol
form.
The literature clearly shows improved hemostatic effects
in both animal and human models [59]. While the efﬁciency
of ﬁbrin sealants is well described in cardiothoracic surgery,
cosmetic surgery, and neurosurgery [50, 59], only a few
similar clinical studies [55, 95] have been performed in
orthopedic surgery using a nonautologous cryoprecipitate-
based ﬁbrinogen. In addition to the improved hemostatic
effect, a lower incidence of postoperative wound healing
disturbances [28], fewer infections, and a shorter length of
hospital stay have been described [72]. The costs, however,
are not negligible: 1 ml of the glue is used for 10 cm2 of
wound surface, and the price is about $175/ml (Baxter®,
Deerﬁeld, IL, USA). The use of these surgical hemostatic
agents is not an acceptable replacement for diligent surgical
hemostasis [59].
Autologous capture and transfusion
There are basically two approaches to autologous capture
and transfusion. The blood can either be washed mechan-
ically before it is given back to the patient (indirect) or it
can be ﬁltered before transfusion (direct). Examples for the
indirect transfusion systems are the discontinuous autotrans-
fusion system (e.g., “Cell Saver®” system, Haemonetics
Corp, Braintree, MA, USA). An example of a continuous
autotransfusion system is the CATS, “C.A.T.S.®” system.
(Fresenius, Bad Homburg, Germany). In both systems, the
blood is centrifuged, dividing the corpuscular elements
according to their density, and washed with a physiological
liquid (e.g., normal saline) [20]. The difference is that in the
discontinuous method, each cycle processes a fully loaded
blood reservoir while the continuous system is almost
independent of the blood volume after priming the system
with a volume of 30 ml. A further advantage of the
continuous technique is the smaller centrifugal force used
to separate the erythrocytes. Also, there is a higher
percentage of removed residual fat particles, which can be
relevant especially in orthopedic surgery. The discontinuous
system, however, is more consistent in removing leukocytes
[20].
The quality of freshly salvaged red blood cells is at least
comparable with stored red blood cells [62]. An absolute
contraindication to indirect autologous transfusion is bacterial
contamination of suctioned blood. Use of such a system in
tumor surgery is relatively contraindicated [4]. Intraoperative
cell salvage has been proven to be an effective method to
avoid allogeneic blood transfusion [81]. Indirect autologous
transfusion systems in orthopedic patients can decrease the
need for allogeneic blood transfusions from 70% to 23%
[43]. Due to high cost (Cell Saver® about $2400, Haemo-
Table 2 Comparison of different alternatives to allogeneic blood transfusion: absolute costs, work load, and efﬁciency
Cost USD Work load Efﬁciency
RBC unit (allogeneic) 0 522–1,183 0 0
Predonation + unknown + 0
EPO ++ 3,000 ++ −
Iron i.v. − 150–450 ++ −
Hemodilution − − −
Platelet gel − 175 − −
Fibrin sealant − 175 − −
Direct retransfusion (Cell Saver®) ++ 2,400 ++ −
Indirect retransfusion (ABT Bellovac®) − 100 ++ −
− less than allogeneic blood transfusion, + more than allogeneic blood transfusion, 0 baseline
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netics Corp, Braintree, MA, USA) associated with the
technique, intraoperative indirect autologous transfusion
might be most suitable for complex and revision surgeries.
Another method for replacing shed blood includes
reinfusion of postoperative drainage as a form of direct
autologous transfusion (e.g., Bellovac ABT®, Astra Tech,
Vienna, Austria). Autologous transfusion of ﬁltered post-
operative blood loss has gained popularity in the orthopedic
community, especially since it is cost-effective and easy to
use. Initially, concerns existed about the safety of
unwashed, ﬁltered blood, but recent studies [40–42] have
maintained that autologous transfusion is safe, provided
certain protocols are followed. These protocols include not
exceeding maximum transfusion volumes, minimum thresh-
old blood loss over 250 ml, and transfusion within 6 h after
surgery, thereby minimizing any hematological or immune
reactions [44]. After 6 h post-op, the system is used as a
regular vacuum drain.
The development of complement split products and
proinﬂammatory cytokines (especially interleukin (IL)-1,
IL-6, and IL-8 and tumor necrosis factor-alpha) in post-
operative drainage has also been cause for concern. These
agents can possibly lead to hypotension, confusion, cardiac
or pulmonary compromise, febrile reactions, coagulopathy,
and even death [2]. Nonetheless, several studies show the
potential beneﬁts (easy handling and low cost: around $100
along with reduced hospital stay), especially after hip and
knee replacement [37, 38, 42, 44, 47, 48]. There are other
trials which describe problems with this system [46] and an
increase in complication rate of 10% (mostly febrile
reactions or tachycardia) [73].
Autologous transfusion of captured blood loss is most
effective if all lost blood can be collected and given back.
This is the case in total knee arthroplasty, where a tourniquet
is used during the operation. In hip arthroplasty, where the
signiﬁcant blood loss occurs during the surgery, this might
not be the case [48]. However, several authors have reported
a positive effect of the direct autologous transfusion method
also after total hip arthroplasty [37, 44, 48].
Conclusions
Concerns about the safety and expense of allogeneic blood
have led to increased research and efforts to improve patient
blood management in orthopedic surgery. Various techni-
ques have also been developed to minimize the need for
autologous blood transfusion.
For example, patients who are anemic preoperatively,
combination therapy with i.v. iron and EPO is optimal [15,
19, 38]. Platelet gel and ﬁbrin sealant can be used
intraoperatively. In addition to the improved hemostatic
effect, proposed beneﬁts include lower incidence of post-
operative wound healing disturbances, fewer infections, and
a shorter length of hospital stay [18]. Intraoperative salvage
has been shown to be effective in patients where predonated
blood is unavailable or when excessive blood loss (>1.5 l) is
expected [36]. Because of the high cost associated with it,
this method should not be used indiscriminately.
Postoperative salvage is still discussed with controversy
because of possible side effects. However, most of the
concerns could be proven wrong, and the method is
inexpensive and easy to use [17, 18, 37, 38, 42, 44, 47, 48].
In summary, many strategies for avoidance of allogeneic
blood transfusion are available and are probably underutilized.
Somemethods are limited to the treating anesthesiologist while
others can be applied intraoperatively by the surgeons. Ideally,
the strategies and methods applied by each party should work
in concert. It is important to know the patient’s preoperative
hemoglobin level and the expected blood loss and to have
some knowledge about the many different alternatives avail-
able for reducing the need for allogeneic blood (see Table 2).
Transfusion triggers should be applied for all patients in the
same way and only be adapted in special cases (e.g., elderly
patients, cardiac history). Preoperative anemia has to be
detected early to treat patients adequately till surgery (e.g., iv
iron, erythropoietin). The intraoperative use of thrombotic
agents on the surgical side and blood saving devices (Cell
Saver®, Bellovac ABT®) on the anesthesiological side can be
used to ﬁnd an optimal and individual treatment for each
patient. Ultimately, each hospital will have to adapt their
methods to the type of surgery performed, as well as their
ﬁnancial resources.
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